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ABSTRACT
Oleoylethanolamide (OEA), an endocannabinoid-like molecule, was revealed to 
modulate lipid metabolism through a peroxisome proliferator-activated receptor-α 
(PPAR-α) mediated mechanism. In present study, we further investigated the activities 
and mechanisms of OEA in ameliorating hepatic fibrosis in Sv/129 mice induced by 
a methionine choline-deficient (MCD) diet or thioacetamide (TAA) treatment. Liver 
fibrosis development was assessed by Hematoxylin-eosin and Sirius red staining. 
Treatment with OEA (5 mg/kg/day, intraperitoneal injection, i.p.) significantly 
attenuated the progress of liver fibrosis in both two experimental animal models by 
blocking the activation of hepatic stellate cells (HSCs). Gene expression analysis of 
hepatic tissues indicated that OEA inhibited the expression of α-smooth muscle action 
(α-SMA) and collagen matrix, fibrosis markers, and genes involved in inflammation 
and extracellular matrix remodeling. In vitro studies showed that OEA inhibited 
transforming growth factor β1-stimulated HSCs activation through suppressing 
Smad2/3 phosphorylation, α-SMA expression and myofibroblast transformation. 
These improvements could not be observed in PPAR-α knockout mice models with 
OEA administration, which suggested all the anti-fibrotic effects of OEA in vivo and 
in vitro were mediated by PPAR-α activation. Collectively, our results suggested that 
OEA exerted a pharmacological effect on modulating hepatic fibrosis development 
through the inhibition of HSCs activation in liver and therefore may be a potential 
therapeutic agent for liver fibrosis.
INTRODUCTION
Liver fibrosis is a common wound healing response 
that may be mounted in response to chronic or repeated 
liver injury. Various etiological factors, including chronic 
hepatitis virus infection, nonalcoholic steatohepatitis 
(NASH), genetic mutations, and cholestatic diseases 
can drive fibrosis. About 25-40% of liver fibrosis cases 
lead to cirrhosis. The same pathological processes 
behind fibrosis have also been linked with hepatocellular 
carcinoma (HCC) [1, 2]. This pathological process is 
characterized by excessive production and deposition 
of proteins of the extracellular matrix (ECM). Hepatic 
stellate cells (HSCs) are recognized as the main producers 
of matrix components in the liver, and play a critical 
role in regulating the production and secretion of the 
ECM. In normal livers, HSCs stay in a quiescent state, 
mainly serving to store vitamin A. These quiescent HSCs 
may trans-differentiate following liver injury however, 
changing into highly-proliferative myofibroblast-like 
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cells that are characterized by the expression of α-smooth 
muscle actin (α-SMA), and excessive production of type I 
collagen (Col1a) and type III collagen (Col3a), which are 
critical components of the ECM. The trans-differentiation 
process of HSCs into myofibroblasts is mainly regulated 
by canonical TGF-β1/Smad signaling. Suppression of 
HSC activation has been proposed as therapeutic strategy 
for the treatment and prevention of liver fibrosis, and novel 
methods for achieving this end are still being sought [3-5].
Peroxisome proliferator-activated receptors 
(PPARs) are members of the nuclear hormone receptor 
family of ligand-activated transcription factors, consisting 
of three different isoforms; PPAR-α, PPAR-β/δ and 
PPAR-γ. PPARs play important roles in controlling 
many physiological processes, including inflammation 
and fibrogenesis. Due to their unique tissue distribution 
patterns, the roles of the three PPARs are at least 
spatially, if not always functionally, distinct. PPAR-α is 
predominantly present in the liver [6]. Previous studies 
have demonstrated that PPAR-α plays a critical role in 
modulation of energy balance and regulation of hepatic 
lipid metabolism [7, 8]. PPAR-α serves as a key signal 
transducer in these pathways, acting downstream of 
sensors such as AMP kinase and aldose reductase. 
A synthetic PPAR-α ligand, fenofibrate, functions to 
reduce serum triglyceride levels, and is clinically used to 
ameliorate plasma lipid disorders at risk of cardiovascular 
disease [9]. Some clinical studies have shown that 
fenofibrate also plays a key role in maintaining the normal 
liver function and improving insulin resistance in NAFLD 
patients [10]. In addition, several observations have 
indicated that PPAR-α might also play a pivotal role in the 
molecular control of fibrogenesis. Previous manuscripts 
have reported that PPAR-α agonists Wy-14643 and 
fenofibrate may prevent the development of hepatic 
fibrosis in the rat thioacetamide (TAA) and methionine 
choline-deficient (MCD) models of liver fibrosis [11, 12]. 
PPAR-α has also been shown to be significantly involved 
with inflammation, as activation of PPAR-α protects 
against hepatic ischemia reperfusion injury in mice 
[13]. Newer studies add to a growing body of evidence 
that PPAR-α could be promising a therapeutic target in 
physiological and pathological processes involved in liver 
diseases [14].
Oleoylethanolamide (OEA), a high affinity 
endogenous ligand of PPAR-α, has been identified to 
play an important role in the treatment of obesity and 
arteriosclerosis [15-17]. In contrast to Wy-14643 and 
fenofibrate, OEA is not a specific ligand for PPAR-α, 
as it can act via other receptors such as the vanilloid 
receptor (TRPV1) and GPR119, allowing it to have 
diverse physiological functions [18, 19]. The role of 
OEA in liver fibrosis has not been well elucidated. In this 
study, we investigated the effect of OEA treatment on the 
progression of liver fibrosis in chronic MCD diet-induced 
and TAA-induced experimental models. We demonstrate 
that OEA acts through a PPAR-α dependent mechanism 
to ameliorate liver fibrosis, and observe that TGF-β1–
mediated HSC activation is also involved. 
RESULTS
OEA reverses MCD diet-induced steatohepatitis, 
liver fibrosis, and leukocyte infiltration 
In order to evaluate the anti-fibrosis role of OEA 
in vivo, we first established a liver fibrosis model using 
MCD diet-induced Sv/129 mice. Histological analysis 
via H&E, Sirius red, and Oil red O staining staining was 
used to gauge the extent of liver injury induced by the 
MCD diet. After 8 weeks MCD diet feeding, both PPAR-α 
knockout mice and WT mice developed moderate steatosis 
and severe hepatocyte ballooning (Figure 1A, S1A, B). 
Significant deposition of fibrillary collagens was also 
detected in the livers of both mice types (Figure 1B), 
along with significantly elevated serum levels of ALT (P 
< 0.001, P < 0.001), AST (P < 0.01, P < 0.01) (Figure 
2A, 2B), and liver levels of TG (P < 0.001, P < 0.01) 
(Figure S1C). In contrast, livers from OEA administration 
groups exhibited ameliorated steatosis and reduced 
hepatocyte ballooning (Figures 1A, S1A, S1B), along 
with the improvements observable via Sirius-red staining 
(Figure 1B). Interestingly, chemical analysis of serum 
and hepatic composition indicate that OEA treatment 
partially prevented the increases of ALT, AST and TG 
levels observed in WT mice given MCD diet (P < 0.01, 
P < 0.05, P < 0.05, respectively), but did not attenuate the 
increase in PPAR-α knockout groups (Figure 2A, 2B and 
Figure S1C). 
In order to further confirm that OEA treatment 
could bring about sustained amelioration of liver fibrosis, 
we next assessed the impact that OEA treatment had on 
immune cells. Histological analysis demonstrated that 
the MCD diet led to significant increases in the number 
of leukocytes in the livers of both WT mice and PPAR-α 
knockout mice, but that treatment with OEA reduced this 
recruitment in WT mice only. (Figure 1A). OEA treatment 
also led to significant reductions in the mRNA expression 
of the adhesion molecules ICAM and VCAM, two key 
proteins responsible for mediating the recruitment of 
immune cells to sites of liver injury in WT MCD-fed mice, 
but could not suppress their expression in the absence of 
PPAR-α (Figure 2C, 2D). From these results, it seems 
clear that OEA can play a potent role in repressing liver 
damage via a PPAR- α dependent mechanism.
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Figure 1: OEA improved liver histology in MCD diet-induced fibrosis mice via PPAR-α. A. Hematoxylin-eosin (HE) 
staining of liver sections in wild-type (WT) mice and PPAR-α knockout mice fed with normal diet, MCD diet, MCD diet combined with 
OEA administration (5 mg/kg/day, i.p.). B.Sirius red staining of liver sections in wild-type (WT) mice and PPAR-α knockout mice fed 
with normal diet, MCD diet, MCD diet combined with OEA administration (5 mg/kg/day, i.p.). Scale bars: 100 μm. n = 6-8 in each group.
Figure 2: OEA alleviated liver injury and inflammation in MCD diet-induced fibrosis mice through PPAR-α. A.-B. 
Effect of OEA on plasma ALT (A) and AST (B) levels in wild-type (WT) mice and PPAR-α knockout mice fed with normal diet, MCD 
diet, MCD diet combined with OEA administration (5 mg/kg/day, i.p.). C.-D. Effect of OEA on liver mRNA expression levels of ICAM 
(C) and VCAM (D) in wild-type (WT) mice and PPAR-α knockout mice fed with normal diet, MCD diet, MCD diet combined with OEA 
administration (5 mg/kg/day, i.p.). Data are shown as means ± s.e.m.; n = 6-8 in each group. ## P < 0.01, ### P < 0.001, * P < 0.05, ** P < 0.01.
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OEA suppresses expression of hepatic pro-
fibrogenic and pro-remodeling genes
To further determine the mechanisms by which 
OEA protects against MCD diet-induced liver fibrosis, 
we then assessed the hepatic mRNA levels of several 
relevant genes through qPCR. As shown in Figure 3A-
3D, expression of TGF-β1, α-SMA, Col1a and Col3a 
significantly increased in both WT mice and PPAR-α 
knockout mice once fed the MCD diet. These increases 
were all substantially reversed by treatment with OEA 
in WT mice, but not in PPAR-α knockout mice. It is 
also noteworthy that the mRNA and protein expression 
levels of PPAR-α were reduced with MCD treatment in 
WT mice, but that these changes were reversed by OEA 
treatment (Figure S2A-S2D). These findings indicate 
that the anti-fibrogenic properties displayed by OEA are 
Figure 3: OEA modulated hepatic fibrotic genes expression in MCD diet-induced fibrosis mice by PPAR-α. The effect of 
OEA on liver mRNA levels of TGF-β A., α-SMA B., Col1a C., Col3a D., TIMP1 E., MMP-2 F., and MMP-9 G. in wild-type (WT) mice 
and PPAR-α knockout mice fed with normal diet, MCD diet, MCD diet combined with OEA administration (5 mg/kg/day, i.p.). Data are 
shown as means ± s.e.m.; n = 6-8 in each group. # P < 0.05, ## P < 0.01, ### P < 0.001, * P < 0.05, ** P < 0.01.
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PPAR-α dependent.
Besides observing changes in the expression of 
pro-fibrogenic genes following OEA therapy, we also 
investigated for possible alterations in the expression of 
genes responsible for managing ECM remodeling. After 
all, it has been suggested that ECM remodeling regulates 
the development of fibrosis and matrix degradation that 
occurs as a consequence of changes in the balance of 
matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) [20]. In both WT and PPAR-α 
Figure 4: Anti-fibrotic effects of OEA in TAA-induced fibrosis mice were mediated by PPAR-α activation. A.-B. 
Hematoxylin-eosin (HE) and Sirius red staining of liver sections. C.-K. Hepatic mRNA levels of ICAM, VCAM, TGF-β, α-SMA, Col1a, 
Col3a, TIMP1, MMP-2, and MMP-9 were determined by quantitative real-time PCR analysis. Results from wild-type (WT) mice and 
PPAR-α knockout mice with saline treatment, TAA treatment (160 mg/kg, i.p.), TAA treatment combined with OEA administration (5 mg/
kg/day, i.p.). Data are shown as means ± s.e.m.; n = 6-8 in each group. ## P < 0.01, ### P < 0.001, * P < 0.05, ** P < 0.01, *** P < 0.001. Scale 
bars: 100 μm (A), 200μm (B).
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knockout mice, the MCD group exhibited significantly 
upregulated levels of TIMP1, MMP2, and MMP9 (Figure 
3E-3G). This type of expression pattern is consistent 
with the expected compensation pattern mounted by 
hepatocytes in response to collagen deposition. Treatment 
with OEA significantly suppressed the induction of these 
remodeling proteins in WT mice (Figure 3E-3G).
OEA attenuates TAA-induced liver fibrosis in 
mice through PPAR-α
In order to further confirm the ability of OEA 
to reverse liver fibrosis, we further tested the effect of 
OEA on TAA-induced hepatic fibrogenesis as a second 
experimental model. Significant liver fibrosis was 
observed in both PPAR-α knockout mice and WT mice 
in response to TAA injection. Similar to the results in 
MCD diet-induced liver fibrosis model, OEA remarkably 
prevented the progression of TAA-induced hepatic 
fibrosis in WT mice, but not in PPAR-α knockout mice, as 
identified by H&E staining and Sirius Red staining (Figure 
4A, 4B). These decreases were associated with significant 
decreases in ICAM and VCAM mRNA expression (Figure 
4C, 4D), a marked decrease in TGF-β and α-SMA mRNA 
expression (Figure 4E, 4F), and a significant reduction 
in Col1a and Col3a mRNA expression (Figure 4G, 4H) 
after OEA administration in TAA-treated WT mice. The 
same reduction pattern was also observed in the mRNA 
expression levels of TIMP1, MMP-2 and MMP-9 after 
OEA treatment in the TAA-treated WT mice (Figure 
4I-4K). By contrast, PPAR-α knockout mice were 
completely insensitive to OEA treatment. Take together 
with our previous results, it seems clear then that OEA can 
generally ameliorate liver fibrosis via a PPAR-α-dependent 
mechanism.
Figure 5: OEA suppressed TGF-β1 induced HSCs activation in vitro via PPAR-α. A.-B. CFSC cells were treated with OEA 
(30 μM, 10 μM, 3 μM) followed by TGF-β1 (5 ng/mL) for 48 h, mRNA expression levels of α-SMA (A) and Col1a (B) were analyzed by 
real-time PCR. C.-D.Immunofluorescence staining (C) and western blot (D) were performed to detect protein expression levels of α-SMA. 
E.-F. CFSC cells were treated with OEA (10 μM) followed by TGF-β1 (5 ng/mL) for 48 h with or without MK886 (10 μM) treatment. The 
α-SMA mRNA expression levels were measured by real-time PCR (E). Protein expression levels of α-SMA were assessed by Western Blot 
(F). Data are shown as means ± s.e.m. of three independent experiments each performed in duplicate. ### P < 0.001, * P < 0.05, *** P < 0.001.
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OEA suppresses TGF-β1 induced HSC activation 
in vitro
Following our observations that OEA attenuation 
of fibrosis is dependent on PPAR-α, we next sought 
to characterize the molecular mechanisms behind the 
attenuation. We first explored for changes in TGF-β1 
signaling, since that pathway is essential for HSC 
activation and liver fibrosis. Numerous lines of evidence 
have shown that TGF-β1 treatment upregulates the 
expression of several pro-fibrogenic genes such as 
α-SMA and Col1a in quiescent fibroblasts [1, 3]. To 
assess the impact of OEA on HSCs activation, the 
expression levels of α-SMA and Col1a in TGF-β1-
stimulated HSCs were examined by qPCR. The mRNA 
levels of α-SMA and Col1a were markedly induced in the 
group of CFSC cells with TGF-β1 (5 ng/mL) stimulation 
for 48h, while the mRNA levels were suppressed when 
treated with OEA in a dose-dependent manner (Figure 
5A, 5B). Immunofluorescence and western blot results 
showed that OEA treatment dose-dependently inhibited 
the protein expression of α-SMA (Figure 5C, 5D), the 
marker of HSC activation. As shown in Figure 5E, 5F, 
the inhibitory effects of OEA on HSCs activation were 
completely blocked by PPAR-α antagonist MK886 
(10 μM). Moreover, the mRNA and protein expression 
levels of PPAR-α were down-regulated with TGF-β1 
stimulation, while OEA treatment restored these 
changes in dose-dependent manner (Figure S2E, S2F). 
In addition, the phosphorylation of Smad 2/3 was 
upregulated in the presence of TGF-β1 stimulation, 
consistent with the observed effects on HSC activation, 
while OEA (10 μM) reduced the phosphorylation of 
Smad2/3 in CFSC simulated with TGF-β1. The altered 
pattern of phosphorylation was also effectively blocked 
by the PPAR-α antagonist GW6471 (10 μM), further 
demonstrating the PPAR-α dependence of the phenomenon 
(Figure 6).
Having verified that PPAR-α impacts the TGF-β1/
Smad pathway, we then examined the pathway to better 
understand the molecular mechanisms by which it may 
influence signaling. Bioinformatics analysis revealed a 
putative binding site for the PPAR-α -RXR-α heterodimer 
on the TGF-β1 promotor. A dual-luciferase reporter assay 
showed that PPAR-α overexpression slightly enhanced 
Figure 6: Inhibitory effect of OEA on TGF-β1-dependent Smad2/3 phosphorylation in vitro was mediated by PPAR-α. 
A. CFSC cells were treated with TGF-β1 (5 ng/mL) for 30 min after 1 h or 12 h OEA (10 μM) treatment, Smad2/3 phosphorylation was 
analyzed by Western Blot. B. CFSC cells were treated with TGF-β1 (5 ng/mL) for 30 min after 1 h OEA (10 μM) treatment, phosphorylation 
of Smad2/3 was analyzed by Immunofluorescence staining. C. CFSC cells were treated with TGF-β1 (5 ng/mL) for 30 min after 1 h OEA 
(10 μM) treatment in the absence or presence of GW6471 (10 μM). Data are shown as means ± s.e.m of three independent experiments. ### 
P < 0.001, ** P < 0.01, *** P < 0.001.
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the TGF-β1 promoter activity (Figure S3A), while OEA 
treatment (30, 10, 3 μM) had no effect (Figure S3B). As 
such, it seems that OEA does not directly repress TGF-β1 
promotor activation by increasing PPAR-α activity or 
expression. We also detected the genes involved into the 
formation and degradation of phospho-Smad2/3. The 
mRNA expression of TGFBR1, Smad4 and PPM1A all 
increased after OEA treatment, while that of TGFBR2 and 
Smad7 was not affected (Figure S4). As such, it seems 
that the influence of OEA-activated PPAR-α on pSmad2/3 
occurs through other mechanisms. 
DISCUSSION
The critical roles played by endogenous ligands 
in mediating cellular signaling is becoming increasingly 
appreciated, with many metabolites now being understood 
to have potent effects on cellular behavior. Our present 
study demonstrates that the endogenous PPAR-α ligand, 
OEA, can significantly suppress the pro-fibrotic cytokine 
TGF-β1 negatively regulate genes in the TGF-β1 signaling 
pathway (α-SMA, collagen 1a, and collagen 3a) in mice 
models of hepatic fibrosis. We also show that OEA 
treatment inhibited the increase of serum ALT, AST, and 
hepatic TG levels, downregulated the adhesion molecules 
ICAM and VCAM, and reduced the gene expression 
of matrix remodeling enzymes TIMP1, MMP2, and 
MMP9 to help slow the pathogenesis of fibrosis. These 
improvements as a result of OEA treatment were lost in 
PPAR-α knockout mice models, showing that the effects 
were almost completely dependent on PPAR-α function. 
Although similar anti-fibrogenic properties of synthetic 
PPAR-α agonists, Wy-14643 and fenofibrate, have been 
reported in TAA, MCD, CCl4 and ethanol-induced liver 
fibrosis [11, 12, 21], previous studies had not elucidated 
the mechanisms behind the response. In addition, off-
target roles of these synthetic ligands may prevent them 
from being fully effective. For instance, Wy-14643 caused 
regression of hepatic fibrosis in MCD dietary feeding 
models, but failed to reduce the increased TGF-β1 mRNA 
expression [11], making it unclear as to if it could be truly 
effective at longer-term amelioration.
Liver fibrosis is presently understood to be a 
process of sterile inflammation caused by a vicious cycle 
of hepatic damage driving HSC activation and worsening 
hepatic damage [12]. Hepatic injury caused by MCD 
diet and TAA increases ER stress and induces MAPK/
ERK activation, which is considered as an indispensable 
step for the overexpression of TGF-β1 mRNA [22]. As 
a critical survival factor for HSCs, TGF-β1 plays an 
important role in triggering and maintaining the vicious 
cycle. In the canonical TGF-β1 signal transduction 
pathway, binding of TGF-β1 to TGF-β1 type I/II receptor 
induces phosphorylation of Smad2/3, which is released 
into the cytosol and results in dimerization with Smad4. 
The heterodimer then translocates into the nucleus 
and regulates transcription [23]. So far, the effects and 
molecular mechanisms of PPAR-α in TGF-β/Smad 
signaling remains elusive. 
It is also possible that different molecular 
mechanisms are responsible for the effects of PPAR-α 
in different cell types. After all, it has been reported that 
Wy14643 could not reduce phospho-Smad2/3 induced by 
TGF-β in rat chondrocytes [24], while, in another paper, 
Wy14643 and clofibrate were reported to significantly 
decrease phosphorylation of Smad2 and Smad3 in 10T1/2 
cells [25]. In the present study, we demonstrate that 
phosphorylation of Smad2/3 was suppressed by OEA 
in CFSC cells, and that these effects were reversed by 
blockage of PPAR-α activation. These results suggested 
that PPAR-α may antagonize the transcriptional effects 
induced by TGF-β1. Previous reports have shown that a 
physical interaction between ligand-activated PPAR-α and 
Smad4 suppressed TGF-β1-induced integrin transcription, 
but a direct binding between them could not be detected 
[26]. Our qRT-PCR results indicate that OEA did not 
reduce the expression of several genes involved in the 
formation of phospho-Smad2/3, (TGFBR1/2 and Smad 4, 
as seen in Figure S4B, S4C, S4F), while it increased the 
mRNA expression of PPM1A (Figure S4D), a phosphatase 
that dephosphorylated and promoted nuclear export of 
activated Smad2/3 to terminate TGF-β signaling [23, 27]. 
It is also possible that the nuclear translocation step is 
affected, and raising the possibility that PPAR-α might act 
as a gatekeeper of sorts for transcription regulation given 
its positioning.
TGF-β1 signaling drives downstream HSC 
expression of α-SMA and collagen type 1a/3a, which 
are key markers for fibrosis. Overexpressed TGF-β1 has 
also been shown to increase ROS levels, which impairs 
PPAR-α expression [12] and inhibits PPAR-α activity [28] 
in hepatocytes. In the present study, TGF-β1 repressed the 
mRNA expression of PPAR-α, which could be reversed 
by SB-431542, a TGF-β pathway inhibitor (Figure S5). 
At the same time, PPAR-α ligands have been identified 
to reduce ROS levels to reverse the PPAR-α reduction 
and subsequently alleviate fibrosis [12]. Administration 
of OEA induced a partial down-regulation of the TGF-β1 
mRNA expression (Figures 3A, 4E) by rescuing PPAR-α 
mRNA (Figure S2) and activating JNK and p38 MAPK 
[29] to inhibit the activation of HSCs, although PPAR-α 
overexpression and OEA did not repress TGF-β promotor 
activity directly (Figure S3). OEA treatment also led to the 
suppression of vital ECM and matrix remodeling genes, 
which contribute greatly to the vicious cycle of worsening 
damage. Taken together, these data demonstrate that 
endogenous PPAR-α agonist OEA effectively suppressed 
activation of HSCs and liver fibrosis through effects on 
TGF-β1. Future work to elucidate mechanisms to increase 





OEA was synthesized in our lab as previously 
described [30]. Recombinant Human TGF-β1 was from 
R&D Systems (Shanghai, China). Dimethyl sulfoxide 
(DMSO), TAA and all other chemicals were obtained 
from Sigma–Aldrich (Shanghai, China) if not mentioned 
otherwise. Dulbecco’s modified Eagle’s medium (DMEM) 
and fetal bovine serum (FBS) were purchased from 
Invitrogen (Shanghai, China). MK886, a PPAR-α inhibitor, 
was purchased from Cayman Chemical (Michigan, USA). 
GW6471, a PPAR-α antagonist, was purchased from R&D 
Systems (Shanghai, China). Alanine transaminase (ALT) 
and aspartate transaminase (AST) commercial assay kits 
were purchased from Nanjing Jiancheng Bioengineering 
Institute (Nanjing, China).
The chemical constituents were dissolved in saline 
supplemented with 5% polyethylene glycol 400 (PEG400) 
and 5% Tween-80 for the in vivo studies. For the in 
vitro studies, OEA was dissolved in DMSO to a series 
concentration of 100-3 mmol/L (stock solution) and then 
diluted in the culture medium to 100-3 µmol/L. 
Animals and treatments
The Sv/129 mice were purchased from the Model 
Animal Research Center (Nanjing, China). The PPAR-α 
knockout mice were obtained from Jackson Laboratory 
(Bar Harbor, ME, USA). All procedures were in 
performed in compliance with the guidelines for animal 
care and use and were approved by the Committee for 
Animal Research at Xiamen University. The mice were 
maintained in a room with controlled temperature (21–
23°C), humidity (55–60%) and lighting (12 h light/dark 
cycles) and given water ad libitum. Mice were randomly 
divided for MCD and TAA experiments. In the MCD-diet 
feeding experiment, wild-type Sv/129 mice and PPAR-α 
knockout mice were each divided into three groups (n 
= 8 /group): (i) control group received normal diet; (ii) 
fed with MCD diet and injected with the vehicle (5% 
Tween-80 + 5% PEG400 + 90% saline, 5 mL/kg/day, 8 
weeks, intraperitoneal injection, i.p.); (iii) fed with MCD 
diet along with OEA administration (5 mg/kg/day; 8 
weeks, i.p.). In another set of experiment, all the wild-
type mice and PPAR-α knockout mice were given standard 
chow diet, and were randomly separated into three groups: 
the control group was not administrated TAA or OEA but 
was injected with the saline; the TAA group was injected 
with TAA (160 mg/kg, three times per week, 6 weeks, 
dissolved in saline, i.p.) plus the corresponding vehicle; 
the OEA group was both injected with TAA and OEA (5 
mg/kg/day; 6 weeks, i.p.).
Liver histological studies
Fresh liver biopsy specimen fixed in the 10% 
neutral-buffered formalin for 3 days and then embedded 
with paraffin for histological examinations. Sections of 5 
μm were cut by a Leica SM2010 R Sliding microtome 
(Shanghai, China) and stained with hematoxylin-eosin 
(H&E) or Sirius red to assess liver damage and fibrosis 
development. To determine the level of lipid accumulation 
in liver, frozen sections of formalin-fixed liver were 
stained with Oil red O. Stained areas were viewed and 
imaged through standard microscopy (Nikon, Shanghai, 
China).
Plasma and hepatic biochemistry assays
For testing liver function, plasma aspartate 
transaminase (ALT), alanine transaminase (AST) and 
hepatic triglyceride (TG) concentration were determined 
by a Thermo Scientific Multiskan GO Microplate 
Spectrophotometer with commercial kits.
Cell culture
CFSC, HSC cell lines were first obtained from 
cirrhotic rat liver, and have a similar phenotype to that of 
early passage primary HSCs. CFSC cells (kind gift from 
Dr. Chenggang Zhu) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin. All 
cells were cultured in 6-well culture plates under 37°C 
and 5% CO 2 in an incubator. The medium was replaced 
every two days, and the cells were harvested and diluted 
at a ratio of 1:3 twice a week. In experiments, HSCs were 
pretreated with the experimental concentration of OEA 
before stimulation with 5 ng/mL TGF-β1.
RNA isolation and cDNA synthesis
Total RNA from liver tissues and cells was extracted 
using the TRIzolTM isolation reagent (Invitrogen) 
according to the protocol provided by the manufacturer. 
cDNA was synthesized from total RNA using a ReverTra 
Ace® qPCR RT kit (Toyobo, Shanghai, China) according 
to the manufacturer’s instructions.
Real-time PCR
Quantification of mRNA was carried out on an 
Applied Biosystems 7300 real-time polymerase chain 
reaction (PCR) system using SYBR® Premix Ex Taq™ II 
(Takara, Dalian, China). The quantitative values of mRNA 




Cells were seeded in 24-well plates and fixed with 
4% paraformaldehyde for 15 min at room temperature 
(RT). after blocking with 2% bovine serum albumin (BSA) 
in PBS for 1 h at RT, the cells were incubated with primary 
Mouse anti-α-SMA (1:100, Sigma-Aldrich) or Rabbit anti-
p-Smad2/3 (1:100, Cell Signalling Technology) antibodies 
diluted with 1% BSA overnight at 4°C, followed by three 
washes with PBS and incubation for 2 h with secondary 
antibodies (donkey anti-mouse IgG conjugated with Alexa 
Fluor 594 or donkey anti-rabbit IgG conjugated with Alexa 
Fluor 594) diluted with 1% BSA for 1 h at RT. Cell nuclei 
were stained with 4,6-diamidino-2-phenylindole (DAPI). 
Images were captured using a laser scanning confocal 
microscope (FluoView 1000; Olympus, Tokyo, Japan).
Western blot analysis
Western blot analysis was conducted as previously 
reports [31]. The target protein was detected using primary 
antibodies as follows: Mouse anti-α-SMA (1:500, Sigma-
Aldrich), Rabbit anti-p-Smad2/3 (1:1000, Cell Signaling 
Technology), Rabbit anti-Smad2/3 (1:1000, Cell Signaling 
Technology), Mouse anti-PPAR-α (1:1000, Abcam) and 
Mouse anti-β-actin (1:5000, Proteintech).
Statistical analysis
 All statistical analyses were performed with 
GraphPad Prism version 5.01 for Windows. Results were 
expressed as the mean ± s.e.m.. Statistical analysis was 
performed via one-way analysis of variance (ANOVA) 
followed by Dunnett’s test for multiple comparisons. P < 
0.05 was considered statistically significant.
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